Empowering Addiction Service Providers
Best Practices for HIV, HCV, and HBV Screening, Prevention, and Linkage to Care
Meeting Slides
HIV, substance use, and intersectional stigma: associations with mental health among persons living with HIV who inject drugs in Russia.
Hook K, Sereda Y, Rossi S, et al. AIDS Behav. 2022;27(2):431-442.
Measuring and addressing stigma within HIV interventions for people who use drugs: a scoping review of recent research.
Lancaster KE, Endres-Dighe S, Sucaldito AD, et al. Curr HIV/AIDS Rep. 2022;19(5):301-311.
Barriers and facilitators to hepatitis C screening and treatment for people with lived experience of homelessness: a mixed-methods systematic review.
Paisi M, Crombag N, Burns L, et al. Health Expect. 2022;25(1):48-60.
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.
Rodger AJ, Cambiano V, Bruun T, et al. Lancet. 2019;393(10189):2428-2438.
PrEP ACCESS, ASSISTANCE, AND INFORMATION
Patient and Provider assistance: PleasePrEPMe.org.
Information about PrEP, nPEP, insurance and insurance rights, finding a PrEP/nPEP provider, and a list of PrEP resources by state
Provider assistance: AETC; AIDS Education & Training Center Program: National Coordinating Resource Center
Supports national HIV priorities by providing training, consultation, and resources
Patient assistance (without insurance).
The PrEP patient assistance program will provide medication at no cost for those who meet income guidelines.
Uninsured 24/7 support online, by phone during business hours and fax enrollment.
Copay assistance (for patients with nongovernment insurance).
Phone number: 1-800-226-2056
Copay assistance/out-of-pocket costs.
ViiV Connect.
PRINTABLE HANDOUTS
Get Protected From HIV
Patient Handout.
HIV PrEP Quick Reference For SUD Centers
Staff Handout.
Dealing with a new HIV diagnosis?
Patient Handout.
What You and Your Patients Need to Know in the Event of a Positive HIV Test
Staff Handout.
CLINICAL PRACTICE GUIDELINES
Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society–USA Panel.
Gandhi RT, Bedimo R, Hoy JF, et al. JAMA. 2023;329(1):63-84.
Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.
US Department of Health and Human Services.
Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update: a clinical practice guideline.
US Public Health Service. Centers for Disease Control and Prevention; 2021.
Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society-USA Panel.
Gandhi RT, et al. JAMA. 2025;333(7):609-628.
Preexposure prophylaxis for HIV: updated recommendations from the 2024 International Antiviral Society-USA Panel.
Landovitz RJ, et al. JAMA. 2025. Epub ahead of print.
Sexually transmitted infections treatment guidelines. 2021.
Centers for Disease Control and Prevention. Last reviewed July 2021.
CDC clinical guidelines on the use of doxycycline postexposure prophylaxis for bacterial sexually transmitted infection prevention, United States, 2024.
Bachmann LH, et al. MMWR Recomm Rep. 2024;73(2);1-8.
